Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
P03-362 - Efficiency of Risperidone in the Treatment of Schizophrenia
View through CrossRef
This prospective study was carried out on 53 in-patients suffering from chronic schizophrenia. Before the Risperidone treatment they were on the convenient antipsychotic therapy - haloperidol average doses 9.6 mg pro die, or Fluphenazine average 4.2 mg pro die.The aim of the study was to follow up therapeutically effects of Risperidone, using PANSS scale for schizophrenia, during two months, by two- weeks visits.ResultsOn average dose of Risperidone 5.1 mg pro die there was found 18.2% reduction on the Positive syndrome scale after two months. Negative syndrome scale showed improvement of 20.5%; General psychopathology scale was reduced for 15.7%. Finally, total PANSS score was reduced 17.2%. Results were also discussed according to sex, age, illness duration and schizophrenia type.ConclusionTherapeutically efficacy of Risperidone has been shown on the positive, as so as the negative schizophrenia symptoms. Better results were in disorganized form of schizophrenia then the paranoid form.
Title: P03-362 - Efficiency of Risperidone in the Treatment of Schizophrenia
Description:
This prospective study was carried out on 53 in-patients suffering from chronic schizophrenia.
Before the Risperidone treatment they were on the convenient antipsychotic therapy - haloperidol average doses 9.
6 mg pro die, or Fluphenazine average 4.
2 mg pro die.
The aim of the study was to follow up therapeutically effects of Risperidone, using PANSS scale for schizophrenia, during two months, by two- weeks visits.
ResultsOn average dose of Risperidone 5.
1 mg pro die there was found 18.
2% reduction on the Positive syndrome scale after two months.
Negative syndrome scale showed improvement of 20.
5%; General psychopathology scale was reduced for 15.
7%.
Finally, total PANSS score was reduced 17.
2%.
Results were also discussed according to sex, age, illness duration and schizophrenia type.
ConclusionTherapeutically efficacy of Risperidone has been shown on the positive, as so as the negative schizophrenia symptoms.
Better results were in disorganized form of schizophrenia then the paranoid form.
Related Results
Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone
Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone
AbstractRecently, the Clinical Pharmacogenetics Implementation Consortium (CPIC) have revised recommendations for the translation of CYP2D6 genotype to phenotype. Changes affect ph...
Use of Risperidone as Augmentation Treatment for Major Depressive Disorder
Use of Risperidone as Augmentation Treatment for Major Depressive Disorder
Objective To review the efficacy and safety of risperidone for augmentation treatment In patients with major depressive disorder who fail to achieve adequate response to antidepres...
9‐Hydroxyrisperidone‐Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder
9‐Hydroxyrisperidone‐Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder
AbstractAlthough our previous study revealed an association between prolactin level and risperidone dosage, data regarding the plasma concentration of risperidone are lacking. Ther...
Pharmacogenomics and Efficacy of Risperidone Long‐Term Treatment in Thai Autistic Children and Adolescents
Pharmacogenomics and Efficacy of Risperidone Long‐Term Treatment in Thai Autistic Children and Adolescents
AbstractThe purpose of this study was to evaluate the association of pharmacogenomic factors and clinical outcome in autistic children and adolescents who were treated with risperi...
Drug Metabolizing Enzyme and Transporter Genes Associated with Plasma Risperidone Level in Thai Autism Spectrum Disorder
Drug Metabolizing Enzyme and Transporter Genes Associated with Plasma Risperidone Level in Thai Autism Spectrum Disorder
BackgroundThe associations between genetic variants of drug metabolizing enzyme and transporter (DMET) genes and steady-state plasma concentrations of risperidone, 9-hydroxyrisperi...
T78. MORTALITY IN PATIENTS WITH SCHIZOPHRENIA ADMITTED FOR INCIDENT ISCHEMIC STROKE: A POPULATION-BASED COHORT STUDY
T78. MORTALITY IN PATIENTS WITH SCHIZOPHRENIA ADMITTED FOR INCIDENT ISCHEMIC STROKE: A POPULATION-BASED COHORT STUDY
Abstract
Background
Evidence shows that schizophrenia is associated with increased incidence of cardiovascular diseases (CVD), i...
T176. INSIGHTS INTO THE ROLE OF ORAL AND GUT MICROBIOME IN THE PATHOGENESIS OF SCHIZOPHRENIA
T176. INSIGHTS INTO THE ROLE OF ORAL AND GUT MICROBIOME IN THE PATHOGENESIS OF SCHIZOPHRENIA
Abstract
Background
The role of oral and gut microbiomes in the pathogenesis of schizophrenia has recently come to light with th...
Clinical stage Alzheimer’s therapy, NNI‐362 promotes TH+ neurons associated with a reversal of motor deficits in AAV‐alpha synuclein model, leaving alpha synuclein unchanged
Clinical stage Alzheimer’s therapy, NNI‐362 promotes TH+ neurons associated with a reversal of motor deficits in AAV‐alpha synuclein model, leaving alpha synuclein unchanged
AbstractBackgroundNNI‐362 is a novel small molecule identified by phenotypic screening to discover compounds that promote new neurons from human neural progenitor cells and have ne...